ONX 0912, a Novel Oral Proteasome Inhibitor (PI), In Patients (pts) With Advanced Refractory or Recurrent Solid Tumours: a Phase 1, Open-label, Dose Escalation Study

被引：1
|
作者：
Papadopoulos, K. [1 ]
Mendelson, D. [2 ]
Tolcher, A. W. [1 ]
Burris, H. A. [3 ]
Gordon, M. [2 ]
Wong, H. [4 ]
Bomba, D. [4 ]
Lee, S. [4 ]
Gillenwater, H. [4 ]
Infante, J. [3 ]
机构：
[1] Start Ctr Canc Care, San Antonio, TX USA
[2] Premiere Oncol, Oncol, Scottsdale, AZ USA
[3] Tennessee Oncol, Oncol, Nashville, TN USA
[4] Onyx Pharmaceut, Oncol, San Francisco, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)70821-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S147 / S147
页数：1
相关论文
共 50 条
  • [1] A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.
    Papadopoulos, K. P.
    Mendelson, D. S.
    Tolcher, A. W.
    Patnaik, A.
    Burris, H. A.
    Rasco, D. W.
    Bendell, J. C.
    Gordon, M. S.
    Kato, G.
    Wong, H.
    Bomba, D.
    Lee, S.
    Gillenwater, H. H.
    Woo, T.
    Infante, J. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] A phase 1, open-label, dose escalation study of AMG 337 in Asian patients (pts) with advanced solid tumors
    Yasui, Hirofumi
    Amore, Benny
    Jiang, Yizhou
    Murugappan, Swaminathan
    Doi, Toshihiko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
    Lin, Chia-Chi
    Arkenau, Hendrik-Tobias
    Lu, Sharon
    Sachdev, Jasgit
    de Castro Carpeno, Javier
    Mita, Monica
    Dziadziuszko, Rafal
    Su, Wu-Chou
    Bobilev, Dmitri
    Hughes, Lorraine
    Chan, Jian
    Zhang, Zhi-Yi
    Weiss, Glen J.
    [J]. BRITISH JOURNAL OF CANCER, 2019, 121 (02) : 131 - 138
  • [4] A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
    Chia-Chi Lin
    Hendrik-Tobias Arkenau
    Sharon Lu
    Jasgit Sachdev
    Javier de Castro Carpeño
    Monica Mita
    Rafal Dziadziuszko
    Wu-Chou Su
    Dmitri Bobilev
    Lorraine Hughes
    Jian Chan
    Zhi-Yi Zhang
    Glen J. Weiss
    [J]. British Journal of Cancer, 2019, 121 : 131 - 138
  • [5] Tolerability of split-dose oprozomib (ONX 0912) in patients with advanced refractory or recurrent solid tumors.
    Papadopoulos, Kyriakos P.
    Mendelson, David S.
    Tolcher, Anthony W.
    Burris, Howard A.
    Gordon, Michael S.
    Bomba, Darrin
    Gillenwater, Heidi H.
    Infante, Jeffrey R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    [J]. Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
  • [7] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
  • [8] TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumours: Dose escalation part of a multicenter open-label phase I trial (SAKK 65/16)
    Hess, D.
    Colombo, I.
    Haefliger, S.
    Bastian, S.
    Rabaglio, M.
    Metaxas, Y.
    Eckhardt, K.
    Kopp, C.
    Hayoz, S.
    Mueller-Schoell, A.
    Kloft, C.
    Sessa, C.
    Stathis, A.
    Joerger, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S490 - S490
  • [9] Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours
    Trarbach, Tanja
    Schultheis, Beate
    Gauler, Thomas C.
    Schneider, Vesile
    Strumberg, Dirk
    Eberhardt, Wilfried E. E.
    Le Scouiller, Stephanie
    Marotti, Marcelo
    Brown, Kathryn H.
    Drevs, Joachim
    [J]. INVESTIGATIONAL NEW DRUGS, 2012, 30 (05) : 1962 - 1971
  • [10] Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours
    Tanja Trarbach
    Beate Schultheis
    Thomas C. Gauler
    Vesile Schneider
    Dirk Strumberg
    Wilfried E. E. Eberhardt
    Stephanie Le Scouiller
    Marcelo Marotti
    Kathryn H. Brown
    Joachim Drevs
    [J]. Investigational New Drugs, 2012, 30 : 1962 - 1971
12345